460 related articles for article (PubMed ID: 23114603)
1. Lymphangioleiomyomatosis - a wolf in sheep's clothing.
Henske EP; McCormack FX
J Clin Invest; 2012 Nov; 122(11):3807-16. PubMed ID: 23114603
[TBL] [Abstract][Full Text] [Related]
2. Lymphangioleiomyomatosis: A Monogenic Model of Malignancy.
Krymskaya VP; McCormack FX
Annu Rev Med; 2017 Jan; 68():69-83. PubMed ID: 28099079
[TBL] [Abstract][Full Text] [Related]
3. Characterization of cells cultured from chylous effusion from a patient with sporadic lymphangioleiomyomatosis.
Grzegorek I; Zuba-Surma E; Chabowski M; Janczak D; Szuba A; Dziegiel P
Anticancer Res; 2015 Jun; 35(6):3341-51. PubMed ID: 26026094
[TBL] [Abstract][Full Text] [Related]
4. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.
Goncharova EA; Goncharov DA; Chisolm A; Spaits MS; Lim PN; Cesarone G; Khavin I; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
Mol Pharmacol; 2008 Mar; 73(3):778-88. PubMed ID: 18094073
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
6. Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.
Krymskaya VP
Proc Am Thorac Soc; 2008 Jan; 5(1):119-26. PubMed ID: 18094094
[TBL] [Abstract][Full Text] [Related]
7. Lymphangioleiomyomatosis: a metastatic lung disease.
Kundu N; Holz MK
Am J Physiol Cell Physiol; 2023 Feb; 324(2):C320-C326. PubMed ID: 36571446
[TBL] [Abstract][Full Text] [Related]
8. Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor gene.
Steagall WK; Pacheco-Rodriguez G; Glasgow CG; Ikeda Y; Lin JP; Zheng G; Moss J
Am J Pathol; 2013 Sep; 183(3):938-50. PubMed ID: 23867796
[TBL] [Abstract][Full Text] [Related]
9. LAM cells biology and lymphangioleiomyomatosis.
Grzegorek I; Drozdz K; Podhorska-Okolow M; Szuba A; Dziegiel P
Folia Histochem Cytobiol; 2013; 51(1):1-10. PubMed ID: 23690211
[TBL] [Abstract][Full Text] [Related]
10. Lymphangioleiomyomatosis: what do we know and what are we looking for?
Harari S; Torre O; Moss J
Eur Respir Rev; 2011 Mar; 20(119):34-44. PubMed ID: 21357890
[TBL] [Abstract][Full Text] [Related]
11. Clinical and molecular insights into lymphangioleiomyomatosis.
Steagall WK; Taveira-DaSilva AM; Moss J
Sarcoidosis Vasc Diffuse Lung Dis; 2005 Dec; 22 Suppl 1():S49-66. PubMed ID: 16457017
[TBL] [Abstract][Full Text] [Related]
12. Effect of beta-agonists on LAM progression and treatment.
Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
[TBL] [Abstract][Full Text] [Related]
13. Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses.
Hayashi T; Kumasaka T; Mitani K; Okada Y; Kondo T; Date H; Chen F; Oto T; Miyoshi S; Shiraishi T; Iwasaki A; Hara K; Saito T; Ando K; Kobayashi E; Gunji-Niitsu Y; Kunogi M; Takahashi K; Yao T; Seyama K
Hum Pathol; 2016 Apr; 50():34-42. PubMed ID: 26997436
[TBL] [Abstract][Full Text] [Related]
14. Protein expression of urotensin II, urotensin-related peptide and their receptor in the lungs of patients with lymphangioleiomyomatosis.
Kristof AS; You Z; Han YS; Giaid A
Peptides; 2010 Aug; 31(8):1511-6. PubMed ID: 20433884
[TBL] [Abstract][Full Text] [Related]
15. Lymphangioleiomyomatosis: Current understanding and potential treatments.
Moir LM
Pharmacol Ther; 2016 Feb; 158():114-24. PubMed ID: 26713679
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin-driven proliferation of cells with mutations in the tumor suppressor gene TSC2.
Ikeda Y; Taveira-DaSilva AM; Pacheco-Rodriguez G; Steagall WK; El-Chemaly S; Gochuico BR; May RM; Hathaway OM; Li S; Wang JA; Darling TN; Stylianou M; Moss J
Am J Physiol Lung Cell Mol Physiol; 2011 Jan; 300(1):L64-72. PubMed ID: 21036916
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factors C and D induces proliferation of lymphangioleiomyomatosis cells through autocrine crosstalk with endothelium.
Issaka RB; Oommen S; Gupta SK; Liu G; Myers JL; Ryu JH; Vlahakis NE
Am J Pathol; 2009 Oct; 175(4):1410-20. PubMed ID: 19717640
[TBL] [Abstract][Full Text] [Related]
18. Giles F. Filley Lecture. Genetics and gene expression in lymphangioleiomyomatosis.
Pacheco-Rodriguez G; Kristof AS; Stevens LA; Zhang Y; Crooks D; Moss J
Chest; 2002 Mar; 121(3 Suppl):56S-60S. PubMed ID: 11893686
[TBL] [Abstract][Full Text] [Related]
19. Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy.
Yu J; Parkhitko AA; Henske EP
Proc Am Thorac Soc; 2010 Feb; 7(1):48-53. PubMed ID: 20160148
[TBL] [Abstract][Full Text] [Related]
20. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.
Glasgow CG; Steagall WK; Taveira-Dasilva A; Pacheco-Rodriguez G; Cai X; El-Chemaly S; Moses M; Darling T; Moss J
Respir Med; 2010 Jul; 104 Suppl 1(Suppl 1):S45-58. PubMed ID: 20630348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
